High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. Issue 4 (12th October 2017)
- Record Type:
- Journal Article
- Title:
- High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. Issue 4 (12th October 2017)
- Main Title:
- High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
- Authors:
- Chesov, Dumitru
Ciobanu, Nelly
Lange, Christoph
Heyckendorf, Jan
Crudu, Valeriu - Abstract:
- Since May 2016 the World Health Organization (WHO) has recommended the treatment of multidrug-resistant tuberculosis (MDR-TB) patients with a standardised treatment regimen of 9–12 months duration if patients fulfil specific eligibility criteria [1]. This shorter-course MDR-TB treatment regimen consists of a combination of seven drugs (clofazimine, ethambutol, high-dose isoniazid, kanamycin, moxifloxacin, prothionamide and pyrazinamide) for 4–6 months, followed by four drugs (moxifloxacin, clofazimine, pyrazinamide and ethambutol) for 5 months. It is based on the results from recent observational cohort studies performed in Bangladesh [2], Cameroon [3] and Niger [4] where this or similar treatment regimens led to high cure rates for MDR-TB. Shortly after the WHO proposed the shorter-course MDR-TB regimen, substantial concerns were raised about the applicability of this regimen for patients with MDR-TB in Europe, where many circulating strains of Mycobacterium tuberculosis have additional resistance to 2nd-line anti-tuberculosis (anti-TB) drugs. Based on results from existing databases with comprehensive records of the drug-susceptibility patterns of M. tuberculosis strains in patients with MDR-TB, several groups reported independently that less than 10% of MDR-TB patients from the WHO European Region were likely to be eligible for this regimen [5–8]. High-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB in MoldovaSince May 2016 the World Health Organization (WHO) has recommended the treatment of multidrug-resistant tuberculosis (MDR-TB) patients with a standardised treatment regimen of 9–12 months duration if patients fulfil specific eligibility criteria [1]. This shorter-course MDR-TB treatment regimen consists of a combination of seven drugs (clofazimine, ethambutol, high-dose isoniazid, kanamycin, moxifloxacin, prothionamide and pyrazinamide) for 4–6 months, followed by four drugs (moxifloxacin, clofazimine, pyrazinamide and ethambutol) for 5 months. It is based on the results from recent observational cohort studies performed in Bangladesh [2], Cameroon [3] and Niger [4] where this or similar treatment regimens led to high cure rates for MDR-TB. Shortly after the WHO proposed the shorter-course MDR-TB regimen, substantial concerns were raised about the applicability of this regimen for patients with MDR-TB in Europe, where many circulating strains of Mycobacterium tuberculosis have additional resistance to 2nd-line anti-tuberculosis (anti-TB) drugs. Based on results from existing databases with comprehensive records of the drug-susceptibility patterns of M. tuberculosis strains in patients with MDR-TB, several groups reported independently that less than 10% of MDR-TB patients from the WHO European Region were likely to be eligible for this regimen [5–8]. High-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB in Moldova http://ow.ly/zUte30eTtRW … (more)
- Is Part Of:
- European respiratory journal. Volume 50:Issue 4(2017)
- Journal:
- European respiratory journal
- Issue:
- Volume 50:Issue 4(2017)
- Issue Display:
- Volume 50, Issue 4 (2017)
- Year:
- 2017
- Volume:
- 50
- Issue:
- 4
- Issue Sort Value:
- 2017-0050-0004-0000
- Page Start:
- Page End:
- Publication Date:
- 2017-10-12
- Subjects:
- Respiratory organs -- Diseases -- Periodicals
Respiration -- Periodicals
616.2 - Journal URLs:
- http://erj.ersjournals.com ↗
http://www.ersnet.org ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=mrj ↗
http://www.ingenta.com/journals/browse/ers/erj?mode=direct ↗ - DOI:
- 10.1183/13993003.01340-2017 ↗
- Languages:
- English
- ISSNs:
- 0903-1936
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24617.xml